- Home
- Companies
- micronesia
- clinical development
Refine by
Industries served
- Medical / Health Care
- Chemical & Pharmaceuticals
- Monitoring and Testing
- Environmental
- Manufacturing, Other
- Agriculture
- Health and Safety
- Banking & Finance / Insurance / Legal
- Defense
- Aerospace & Air Transport
- Retail
- Waste and Recycling
- Air and Climate
- Soil and Groundwater
- University / Academia / Research
- Food and Beverage
- Energy
- Construction & Construction Materials
Clinical Development Suppliers Serving Micronesia
287 companies found
based inLeverkusen, GERMANY
Bayer is a global enterprise with core competencies in the life science fields of healthcare and nutrition. We design our products and services to help people and planet thrive by supporting efforts to address the unprecedented global challenges ...
Small molecules (SMOLs) have long been in the focus of modern medicine. Over the last century, their advent revolutionized healthcare and improved the lives of patients all over the world. Most of today´s SMOLs exert their function by binding ...
based inHollister, CALIFORNIA (USA)
For 70 years, Charles River employees have worked together to assist in the discovery, development and safe manufacture of new drug therapies. When you join our family, you will have a significant impact on the health and well-being of people across ...
Market pressures continue to change the focus and structure of the drug development industry with a heavy emphasis on accelerating preclinical development to move the most efficacious therapies into the ...
based inGangnam-gu, SOUTH KOREA
MitoImmune Therapeutics Inc. is a drug discovery and development biotech company that harnesses the power of mitochondria and its proprietary technology targeting mitochondria as the source for developing new potential breakthrough therapeutics. Our ...
based inMechelen, BELGIUM
Galapagos discovers, develops and commercializes small molecule medicines with novel modes of action. Our pipeline comprises discovery through to Phase 3 programs in inflammation, fibrosis, and other indications. Our first medicine is approved and ...
The SIK program is a strategic effort to develop assets inhibiting salt-inducible kinases (SIK) as a novel target class in inflammation which we discovered with our proprietary target discovery platform. These molecules inhibit the different members ...
based inCambridge, MASSACHUSETTS (USA)
Sumitomo Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. This U.S. entity, together with the oncology research and development teams in Japan, Cancer ...
based inLondon, UNITED KINGDOM
Treos Bio is a clinical stage company introducing a disruptive computational technology to change the paradigm of cancer immunotherapy development by resolving the dual challenges of patient and tumor heterogeneity. We use proprietary therapeutic ...
At TREOS we use knowledgebase and algorithm embedded in PASCal (Personal Antigen Selection Calculator) tool to develop personal cancer immunotherapies. PASCal supports the development of immunotherapies for single individuals and a population of ...
based inWichita, KANSAS (USA)
Neotherma Oncology is led by experienced healthcare executives who are working toward the dream of more effective treatments for cancer. NeoTherma Oncology is developing a groundbreaking type of radio frequency (RF) thermal treatment for deep solid ...
based inSan Jose, CALIFORNIA (USA)
Precigenome LLC is located in the heart of Silicon Valley, San Jose, California, USA. We have been focusing on developing nanoparticle synthesis systems and solutions for preparation of lipid nanoparticles, liposomes, & PLGA nanoparticles. We also ...
based inMonroe Township, NEW JERSEY (USA)
We are a multinational company active in the life science sector, a world leader in imaging diagnostics. Every day we seek and perfect increasingly advanced and sustainable techniques and solutions to open new paths in diagnostic imaging. So that ...
based inMilford, MASSACHUSETTS (USA)
SeraCare is a leading partner and supplier of diagnostic quality controls, biological materials, and reagents to in vitro diagnostics developers, clinical laboratories, and life science researchers worldwide. Since the early 1980s, we have supported ...
based inFlower Mound, TEXAS (USA)
Ceutical Laboratories has an evolving quality system to meet the ever-changing demands of the regulatory environment for pharmaceuticals, medical devices, nutraceuticals, cosmetic industries, veterinary markets, otc and dietary supplements. Ceutical ...
based inRochester, MINNESOTA (USA)
Ambient’s healthcare data visualization solution changes the way providers operate by providing operational and clinical efficiency. This Minnesota-based company in Rochester delivers healthcare data visualization and surveillance tools to hospitals ...
Ambient’s Tele-Sepsis™ solution provides expert clinical staffing along with FDA Class II cleared software for automating, notifying, and tracking delivery of sepsis care in healthcare organizations. Tele-Sepsis™ has been proven to ...
based inBentley DC, AUSTRALIA
Ozgene is one of the leading companies providing genetically modified mice for researchers around the world. We offer a full spectrum of pre-clinical capabilities from the development of mouse models through to breeding, characterisation and ...
based inHuntington Beach, CALIFORNIA (USA)
Nordson Medical (Nasdaq: NDSN) is a global expert in the design, development, and manufacturing of complex medical devices and component technologies. As a single-source partner, we enable our customers to save costs, speed time to market, and ...
based inLos Altos, CALIFORNIA (USA)
LifeWave Biomedical is developing a connected health solution that improves the clinical management of patients living with congestive heart failure (CHF) in hospital, ambulatory, and home settings. Steve is a 30 year veteran of the high tech ...
based inGroningen, NETHERLANDS
ViciniVax is a Dutch clinical stage biopharmaceutical company. It is a spin-off from the University Medical Center Groningen, the Netherlands, developing therapeutic cancer vaccines. Our first product candidate Vvax001, a therapeutic cancer vaccine ...
Our first product candidate Vvax001, a therapeutic cancer vaccine against (pre)malignant cervical lesions, is currently in clinical development. We outsource process development and GMP ...
based inCottesloe, AUSTRALIA
Neuroscientific Biopharmaceuticals is an Australian public company (ASX:NSB) developing novel peptide-based pharmaceutical products that target a number of neurological disorders and diseases of the eye that have high unmet medical need. Our vision ...
Multiple indications with unmet medical need. “Our company goal is to create new products that reach their target in the brain and act as a protector against nerve cells injury. Currently, there are no approved drugs that can slow down or halt ...
based inSeongnam-si, SOUTH KOREA
LISCure Biosciences Provides Novel Therapeutics to Patients with Refractory Diseases Using the LMT Platform. LISCure is developing the world’s first injectable immuno-oncology program using non-pathogenic microorganisms. We focus on the development ...
The LMT (LISCure Microbiology-based Technology) platform is an innovative tool to keep discovering and analyzing microbial and genome-based drug candidates. LMT (LISCure Microbiology-based Technology) Platform Consists of the Therapeutic Screening ...
based inMississauga, ONTARIO (CANADA)
Covalon Technologies Ltd. (Covalon) develops and commercializes proprietary technologies for major medical device manufacturers. Our partners include the top medical device companies, leaders in urology, wound care, vascular access, venture capital, ...
based inSomerville, MASSACHUSETTS (USA)
Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted ...
CP101, an orally administered, Complete Consortia product candidate in late-stage clinical development for the prevention of recurrent C. difficile infection is also being developed for the ...
